Corpus ID: 37522256

Security market reaction to FDA fast track designations.

@article{Anderson2010SecurityMR,
  title={Security market reaction to FDA fast track designations.},
  author={C. W. Anderson and Y. Zhang},
  journal={Journal of health care finance},
  year={2010},
  volume={37 2},
  pages={
          27-48
        }
}
Pharmaceutical firms can apply for the Food and Drug Administration to 'fast track' research and de velopment on new drugs, accelerating clinical trials and expediting regulatory review required prior to marketing to consumers. We investigate security market reaction to more than 100 fast track designations from 1998 to 2004. Fast track designation appears to enhance investor recognition of firm value. Specifically, fast track designation coincides with abnormal trading volume and excess daily… Expand
The Signaling Effects of the US Food and Drug Administration Fast‐Track Designation
Pharmaceutical firms are reluctant to disclose proprietary information about a drug's likelihood of approval by the U.S. Food and Drug Administration (FDA) for fear of losing their competitiveExpand
The Signaling Effects of FDA Drug Designations
TLDR
This analysis examines three questions regarding the signaling effects of the FDA fast-track designation and finds the strength of a signal is measured by the change in the stock price of a firm after an announcement, which is known as the cumulative abnormal return (CAR). Expand
Do investors value the FDA orphan drug designation?
  • K. L. Miller
  • Business, Medicine
  • Orphanet Journal of Rare Diseases
  • 2017
TLDR
The orphan designation appears to be successful at generating positive value for companies, as seen by the positive and significant average increases in stock price. Expand
Understanding Life under Public Scrutiny: The U.S. Bio-pharmaceutical Industry Experience
The pharmaceutical and biotechnology industry is a major component of the global health economy, of which, the U.S. plays an important role and attracts firms from all over the world to operate andExpand
The signaling effects of incremental information: Evidence from stacked US Food and Drug Administration designations
The US Food and Drug Administration offers multiple designations for drugs under development, such as the fast-track designation (for drugs that treat serious conditions with unmet medical need) andExpand
Nontraditional Banking Activities and Bank Failures During the Financial Crisis
We test whether income from nontraditional banking activities contributed to the failures of hundreds of U.S. commercial banks during the financial crisis. Estimates from a multi-period logit modelExpand

References

SHOWING 1-10 OF 45 REFERENCES
Fast Track Product Designation under the Food and Drug Administration Modernization Act: The Industry Experience
TLDR
There are indications that fast track designation will be the improvement Congress intended, and the biotechnology and pharmaceutical sponsors of 32 fast track designated products identified from public information sources are surveyed. Expand
Beyond fast track for drug approvals.
TLDR
The authors propose that the FDA make rapid approval of new molecularly targeted cancer therapies contingent on sponsors' agreement to invest in research designed to identify subgroups of patients who are likely to have a response to treatment. Expand
From idea to market: the drug approval process.
TLDR
The drug development process is described based on a review of the literature and Web sites addressing FDA processes and policies and it is claimed that changes in the approval process help patients with debilitating diseases that were previously denied critical medication because of bureaucratic regulations. Expand
Cost of innovation in the pharmaceutical industry.
The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-taxExpand
The price of innovation: new estimates of drug development costs.
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drugExpand
Advertising, R&D Expenditures and the Market Value of the Firm
This article attempts to determine whether investors recognize the long-term, or asset-like, characteristics of advertising and R&D expenditures. In previous studies, it has been conventional toExpand
The Food and Drug Administration Modernization ACT and the Food and Drug Administration: Metamorphosis or Makeover?
TLDR
The results from the first two years of implementation of the major FDAMA provisions for drugs and biologicals are reviewed and whether FDA is capable of change is considered, as well as what the real message of FDAMA is. Expand
Volume, Opinion Divergence and Returns: A Study of Post-Earnings Announcement Drift
This paper examines the relationship between post-earnings announcement returns and different measures of volume at the earnings date. We find that post-event returns are strictly increasing in theExpand
Volume, Opinion Divergence and Returns: A Study of Post-Earnings Announcement Drift
This paper examines the relationship between post-earnings announcement returns and different measures of volume at the earnings date. We find that post-event returns are strictly increasing in theExpand
The Price of Innovation
I live on an island in the middle of the Niagara River. Most Sunday mornings when the weather cooperates, I along with several family members and friends, ride bicycles around the island. It’s aExpand
...
1
2
3
4
5
...